DDInter1678 DDInter899
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
Sirolimus {u} (Compound) upregulates {v} (Gene) WDR13
Sirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologic Activity
Sirolimus {u} (Compound) downregulates {v} (Gene) IMP3
Sirolimus {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lansoprazole
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Sirolimus (Compound) resembles Pimecrolimus (Compound)
Sirolimus (Compound) binds ABCB1 (Gene)
Sirolimus (Compound) upregulates WDR13 (Gene)
Sirolimus (Compound) is included by Decreased Immunologic Activity (Pharmacologic Class)
Sirolimus (Compound) downregulates IMP3 (Gene)
Sirolimus (Compound) causes Aspartate aminotransferase increased (Side Effect)
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib